Source: International Congress 2017 – Management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Mäenpää (Mölndal, Sweden). Target engagement confirmed in man with a dipeptidyl peptidase 1 inhibitor. 3251

Member's Comments

No comment yet.

Related content which might interest you: Dipeptidyl peptidase IV and aminopeptidase N activity in children with sleep apnea Source: Eur Respir J 2005; 26: Suppl. 49, 357s Year: 2005 Dipeptidyl peptidase I (DPPI) cleaves surfactant protein D (SP-D): A mechanism for immune compromise in the lung Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Human airway trypsin-like protease stimulates protease activated receptors and interactions of these receptors Source: International Congress 2019 – Immunopathological mechanisms of lung disease Year: 2019 Human alpha-1 proteinase inhibitor (tal6004) manufacturing process and pathogen safety Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Dipeptidyl peptidase-4 (DPP-4) may predict response to tralokinumab in patients with asthma Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Development of the first protease multiplex immunoassay for active neutrophilic serine protease biomarkers Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 LATE-BREAKING ABSTRACT: Lack of association between circulating dipeptidyl peptidase-4 and type 2 biomarkers in asthma; data from U-BIOPRED and BIOAIR cohorts Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology Year: 2016 LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015 Expression of adamalysin proteases (A Disintegrin And Metalloprotease) and their inhibitors in sputum from asthmatics Source: Eur Respir J 2006; 28: Suppl. 50, 445s Year: 2006 A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: Lung Science Conference 2015 Year: 2015 AZD9668: Pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE) Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010 SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition Source: Eur Respir J 2011; 37: 1083-1090 Year: 2011 Type II transmembrane serine protease matriptase is a mediator of pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004 Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014 NIK-616,a new type of selective PDE IV inhibitor with reduced emetic activity Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002 Phase 1 trial of a novel chemokine inhibitor Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 Alpha-1 antitrypsin genotypes and associated inhibitory activity towards neutrophil serine proteinases, in vitro Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015